TY -的T1 -口服精氨酸补充cystic fibrosis patients: a placebo-controlled study JF - European Respiratory Journal JO - Eur Respir J SP - 62 LP - 68 DO - 10.1183/09031936.04.00086104 VL - 25 IS - 1 AU - Grasemann, H. AU - Grasemann, C. AU - Kurtz, F. AU - Tietze-Schillings, G. AU - Vester, U. AU - Ratjen, F. Y1 - 2005/01/01 UR - //www.qdcxjkg.com/content/25/1/62.abstract N2 - Exhaled nitric oxide (eNO) is decreased in cystic fibrosis (CF). The effect of oral L-arginine, the precursor of enzymatic nitric oxide (NO) formation, on airway NO in patients with CF was studied. In a pilot study, oral L-arginine was given in a single dose of 200 mg·kg−1 body weight to eight healthy controls and eight CF patients. Subsequently, the same L-arginine dose was given to 10 patients with CF (five females) t.i.d. for 6 weeks in a randomised double-blind placebo-controlled crossover study. A single dose of oral L-arginine resulted in a 5.5-fold increase of L-arginine in plasma and a 1.3-fold increase of L-arginine in sputum after 2 h. Maximum eNO, within 3 h of L-arginine intake, increased significantly in both CF patients (5.4±2.1 ppb versus 8.3±3.5 ppb) and controls (18.0±8.1 ppb versus 26.4±12.3 ppb). Supplementation of L-arginine for 6 weeks resulted in a sustained increase in eNO compared to placebo (9.7±5.7 ppb versus 6.3±3.1 ppb). An effect of L-arginine supplementation on forced expiratory volume in one second was not observed. These data indicate that airway nitric oxide formation in cystic fibrosis patients can be augmented with oral L-arginine supplementation. ER -